Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
M M C Hendriks, K S A Schweren, A Kleij, M A H Berrevoets, E de Jong, P van Wijngaarden, H S M Ammerlaan, A N Vos, S van Assen, K Slieker, E H Gisolf, M G Netea, J Ten Oever, I J E Kouijzer
BACKGROUND: Risk stratification to categorize patients with Staphylococcus aureus bacteremia (SAB) as low- or high-risk for metastatic infection may direct diagnostic evaluation and enable personalized management. We investigated the frequency of metastatic infections in low-risk SAB patients, their clinical relevance, and whether omission of routine imaging is associated with worse outcomes. METHODS: We performed a retrospective cohort study in seven Dutch hospitals among adult patients with low-risk SAB, defined as hospital-acquired infection without treatment delay, absence of prosthetic material, short duration of bacteremia, and rapid defervescence...
April 5, 2024: Clinical Infectious Diseases
#22
JOURNAL ARTICLE
John M Cafardi, Hong T Lin, Lana Lange, Lacey Kelley, Kelly Lemon, Elizabeth A Odegard, Heidi L Meeds, Jason T Blackard, Judith Feinberg
We evaluated vertical transmission and linkage to care in women with HCV and history of injection drug use employing co-localized testing and treatment. Transmission occurred in 1 of 23 infants, with mother-infant genetic distance of 1.26%. Rates for infant testing, maternal linkage and cure were 77%, 52%, and 100%, respectively.
April 5, 2024: Clinical Infectious Diseases
#23
JOURNAL ARTICLE
Davide Moschese, Angelo Roberto Raccagni, Andrea Giacomelli, Antonio Piralla, Roberto Rossotti, Alessandro Raimondi, Daniele Tesoro, Luigi Vezzosi, Maurizio Gulletta, Nicola Clementi, Serena Venturelli, Susanna Benardon, Davide Ricaboni, Dario Bernacchia, Alessandro Mancon, Francesca Rovida, Federica Attanasi, Danilo Cereda, Maria Rita Gismondo, Andrea Gori, Giuliano Rizzardini, Spinello Antinori, Fausto Baldanti, Angelo Valerio Marzano, Giulia Marchetti, Francesco Castelli, Antonella Castagna, Silvia Nozza, Davide Mileto
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#24
JOURNAL ARTICLE
Ryan K Shields, Wendy Y Cheng, Kalé Kponee-Shovein, Daniel Indacochea, Chi Gao, Fernando Kuwer, Ashish V Joshi, Fanny S Mitrani-Gold, Patrick Schwab, Diogo Ferrinho, Malena Mahendran, Lisa Pinheiro, Jimmy Royer, Madison T Preib, Jennifer Han, Richard Colgan
BACKGROUND: In clinical practice, challenges in identifying patients with uncomplicated urinary tract infections (uUTIs) at risk of antibiotic non-susceptibility may lead to inappropriate prescribing and contribute to antibiotic resistance. We developed predictive models to quantify risk of non-susceptibility to four commonly prescribed antibiotic classes for uUTI, identify predictors of non-susceptibility to each class, and construct a corresponding risk categorization framework for non-susceptibility...
April 4, 2024: Clinical Infectious Diseases
#25
JOURNAL ARTICLE
Kaleb H Wolfe, Virginia M Pierce, Romney M Humphries
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs)...
April 4, 2024: Clinical Infectious Diseases
#26
JOURNAL ARTICLE
Edward R Cachay, Tari Gilbert, Huifang Qin, Wm Christopher Mathews
BACKGROUND: Due to the heterogeneity of risk for invasive anal cancer (IAC) among people with human immunodeficiency virus (PWH), we investigated predictors of IAC and described outcomes among those with a cancer diagnosis. METHODS: Using a longitudinal inception cohort of anal cancer screening, we evaluated risk factors and outcome probabilities for incident IAC in Cox models. Screening included anal cytology and digital anorectal examination, and, if results of either were abnormal, high-resolution anoscopy...
April 4, 2024: Clinical Infectious Diseases
#27
JOURNAL ARTICLE
Genovefa A Papanicolaou, Robin K Avery, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young, Martha Fournier, Rose Ann Murray, Jingyang Wu, Tien Bo, Drew J Winston
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#28
JOURNAL ARTICLE
Jose F Camargo, Yoichiro Natori
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#29
JOURNAL ARTICLE
Paula Rodríguez-Molino, Marc Tebruegge, Antoni Noguera-Julian, Olaf Neth, Katy Fidler, Folke Brinkmann, Talia Sainz, Inga Ivaskeviciene, Nicole Ritz, Maria Joao Brito, Tiago Milheiro Silva, Vira Chechenieva, Maryna Serdiuk, Laura Lancella, Cristina Russo, Aleix Soler-García, Maria Luisa Navarro, Renate Krueger, Cornelia Feiterna-Sperling, Anna Starshinova, Antonina Hiteva, Anna Hoffmann, Paulius Kalibatas, Andrea Lo Vecchio, Sara Maria Scarano, Matilde Bustillo, Daniel Blázquez Gamero, María Espiau, Danilo Buonsenso, Lola Falcón, Louise Turnbull, Elena Colino, Santiago Rueda, Charlotte Buxbaum, Begoña Carazo, Cristina Alvarez, Marta Dapena, Anabel Piqueras, Svetlana Velizarova, Iveta Ozere, Florian Götzinger, Marta Pareja, Maria Isabel Garrote Llanos, Beatriz Soto, Sonia Rodríguez Martín, Jose Javier Korta, Beatriz Pérez-Gorricho, Mercedes Herranz, Ángel Hernández-Bartolomé, Mariana Díaz-Almirón, Malte Kohns Vasconcelos, Laura Ferreras-Antolín, Begoña Santiago-García
BACKGROUND: In high-resource settings the survival of immunocompromised (IC) children has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools and outcome of IC children with TB in Europe. METHODS: Multicentre, matched case-control study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), capturing TB cases <18 years diagnosed 2000-2020...
April 3, 2024: Clinical Infectious Diseases
#30
JOURNAL ARTICLE
Anthony T Podany, Yoninah Cramer, Marjorie Imperial, Susan L Rosenkranz, Anchalee Avihingsanon, Roberto Arduino, Wadzanai Samaneka, Irina Gelmanova, Rada Savic, Susan Swindells, Rodney Dawson, Anne F Luetkemeyer
BACKGROUND: One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for TB prevention in people with HIV (PWH). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. ACTG A5372 evaluated the effect of 1HP on the pharmacokinetics of twice daily dolutegravir. METHODS: A5372 was a multicenter, pharmacokinetic study in PWH (≥18 years) already on dolutegravir-containing antiretroviral therapy with HIV RNA < 50 copies/mL...
April 3, 2024: Clinical Infectious Diseases
#31
JOURNAL ARTICLE
Nadine Tschumi, Blaise Lukau, Katleho Tlali, Lipontso Motaboli, Mpho Kao, Mathebe Kopo, Kathrin Hänggi, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka, Karoline Leuzinger, Jennifer A Brown, Niklaus D Labhardt
BACKGROUND: Since 2019, the World Health Organization has recommended dolutegravir-based antiretroviral therapy (ART) as the preferred regimen for HIV management. Large-scale programmatic transitioning to dolutegravir-based ART was subsequently implemented across Africa, often in the absence of recent viral load testing and without access to genotypic resistance testing (GRT) in case of viremia. METHODS: This study assessed for emerging dolutegravir resistance in the routine care Viral Load Cohort North-East Lesotho (VICONEL)...
April 3, 2024: Clinical Infectious Diseases
#32
JOURNAL ARTICLE
Ian McGovern, Katherine Cappell, Alina N Bogdanov, Mendel D M Haag
BACKGROUND: Research on influenza burden in adults has focused on crude subgroups with cut-points at 65-years, limiting insight into how burden varies with increasing age. This study describes the incidence of influenza-related outpatient visits, emergency room (ER) visits, and hospitalizations, along with healthcare resource use and complications in the aging adult population. METHODS: Individuals ≥18 years of age in the United States were evaluated retrospectively in five seasonal cohorts (2015-2020 seasons) in strata of age with 5-year increments...
April 3, 2024: Clinical Infectious Diseases
#33
JOURNAL ARTICLE
Emily A G Faherty, Taylor Holly, Yasmin P Ogale, Hillary Spencer, Ashley M Becht, Gordon Crisler, Michael Wasz, Patrick Stonehouse, Hannah J Barbian, Christy Zelinski, Alyse Kittner, Dorothy Foulkes, Kendall W Anderson, Tiffany Evans, Lavinia Nicolae, Amber Staton, Carla Hardnett, Michael B Townsend, William C Carson, S Satheshkumar Panayampalli, Christina L Hutson, Crystal M Gigante, Laura A S Quilter, Susan Gorman, Brian Borah, Stephanie R Black, Massimo Pacilli, David Kern, Janna Kerins, Andrea M McCollum, Agam K Rao, Irina Tabidze
BACKGROUND: After months of few mpox cases, an increased number of cases were reported in Chicago during May 2023; predominantly among fully vaccinated patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. METHODS: We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics, mpox vaccine status, and vaccine administration routes...
April 3, 2024: Clinical Infectious Diseases
#34
JOURNAL ARTICLE
Nakwon Kwak, Emily Henkle, Hyeontaek Hwang, Doosoo Jeon, Byung Woo Jhun, Kyung-Wook Jo, Young Ae Kang, Hyung-Jun Kim, Joong-Yub Kim, Young Ran Kim, Yong-Soo Kwon, Jae Ho Lee, Jeongha Mok, Youngmok Park, Tae Sun Shim, Hojoon Sohn, Jake Whang, Jae-Joon Yim
BACKGROUND: Improving health-related quality of life (HRQOL) has emerged as a priority in the management of nontuberculous mycobacterial pulmonary disease (NTM-PD). We aimed to evaluate HRQOL and its changes after 6 months' treatment in patients with NTM-PD. METHODS: The NTM-KOREA is a nationwide prospective cohort enrolling patients initiating treatment for NTM-PD in 8 institutions across South Korea. We conducted the Quality of Life-Bronchiectasis (QOL-B) at 6-month intervals and evaluated baseline scores (higher scores indicate better quality of life) and changes after 6 months' treatment...
April 2, 2024: Clinical Infectious Diseases
#35
JOURNAL ARTICLE
Wei-Ju Su, Huey-Ling Chen, Shu-Fong Chen, Yu-Lun Liu, Ting-Ann Wang, Yee-Chuan Ho, Mei-Hwei Chang
BACKGROUND: Evaluation of the impact on mother-to-child transmission (MTCT) of a HBV-prevention program that incorporates maternal antiviral prophylaxis is hindered by the limited availability of real-world data. METHODS: This study analyzed data on maternal HBV screening, neonatal immunization, and post-vaccination serologic testing (PVST) for HBsAg among at-risk infants born to HBV carrier mothers from the National Immunization Information System during 01/01/2008-31/12/2022...
April 2, 2024: Clinical Infectious Diseases
#36
JOURNAL ARTICLE
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, Lucie de Gastines, Drifa Belhadi, Claire Fougerou-Leurent, Nathan Peiffer-Smadja, Noémie Mercier, Christelle Delmas, Assia Ferrane, Aline Dechanet, Julien Poissy, Hélène Espérou, Florence Ader, Maya Hites, Claire Andrejak, Richard Greil, José-Artur Paiva, Thérèse Staub, Evelina Tacconelli, Charles Burdet, Dominique Costagliola, France Mentré, Yazdan Yazdanpanah, Alpha Diallo
BACKGROUND: We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with Coronavirus Disease 2019 (COVID-19) receiving remdesivir plus standard of care (SoC) compared to SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases. METHODS: This post-hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19 (NCT04315948)...
March 29, 2024: Clinical Infectious Diseases
#37
JOURNAL ARTICLE
Jacopo Angelini, Shuhan Liu, Simone Guiliano, Sarah Flammini, Luca Martini, Carlo Tascini, Massimo Baraldo, Manjunath P Pai
Precision daptomycin dosing faces clinical implementation barriers despite known exposure-safety concerns with the use of twice the regulatory-approved doses. We propose achieving a single 7-11 hour post-dose plasma target concentration of 30 mg/L to 43 mg/L to be a practical starting point to facilitate precision daptomycin dosing.
March 29, 2024: Clinical Infectious Diseases
#38
JOURNAL ARTICLE
Robert L Gottlieb, Andre C Kalil
No abstract text is available yet for this article.
March 29, 2024: Clinical Infectious Diseases
#39
(no author information available yet)
No abstract text is available yet for this article.
March 29, 2024: Clinical Infectious Diseases
#40
JOURNAL ARTICLE
Christina A Rostad, Robert L Atmar, Emmanuel B Walter, Sharon Frey, Jeffery L Meier, Amy C Sherman, Lilin Lai, Rachel Tsong, Carol M Kao, Vanessa Raabe, Hana M El Sahly, Wendy A Keitel, Jennifer A Whitaker, Michael J Smith, Kenneth E Schmader, Geeta K Swamy, Getahun Abate, Patricia Winokur, Wendy Buchanan, Kaitlyn Cross, Ashley Wegel, Yongxian Xu, Inci Yildirim, Satoshi Kamidani, Nadine Rouphael, Paul C Roberts, Mark J Mulligan, Evan J Anderson
INTRODUCTION: A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs. METHODS: Healthy adults (n=180), ages 19-50 years, were enrolled into this partially-blinded, randomized, multi-center Phase 2 clinical trial...
March 27, 2024: Clinical Infectious Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
